ImmunoPrecise Antibodies (IPA) Misses Q4 EPS by 5c

ImmunoPrecise Antibodies (NASDAQ: IPA) reported Q4 EPS of ($0.05). Revenue for the quarter came in at $6.98 million.

For earnings history and earnings-related data on ImmunoPrecise Antibodies (IPA) click here.

You May Also Be Interested In

• Futu Holdings Limited (FUTU) Tops Q2 EPS by 23c
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c
• Jefferies Starts Bajaj Housing Finance (BAJAJHFL:IN) at Hold